In this sense, the combinational use of the mutation markers discussed above might be prognostically useful since RAS mutation, RET/PTC, and likely PAX8/PPARγ predict a less aggressive course of thyroid cancer than the BRAF mutation. The gene discussed is BRAF; the disease is thyroid gland carcinoma.